MedCity News

The Value-based Care Throughline to Healthcare Quality and Safety

With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better

Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes.

By Frank Vinluan

Hospitals, Health Tech

The Top 3 Reasons That Hospitals’ Tech Pilots Fail

Justin Brueck, vice president of innovation and research at Endeavor Health, shared three main reasons that technology pilots end up being unsuccessful at health systems.

By Katie Adams

Latest News

MedCity Influencers

Making Access to AI-enabled Medical Devices Equitable for All

If Medicare acts, the potential of AI-enabled technologies to improve healthcare outcomes for patients, regardless of their geographic location or socioeconomic status, will be closer to being fully realized.

By Julianne Malveaux

Health Tech

Boulder Care Secures $35M To Advance Virtual Addiction Care

Boulder Care's Series C funding round was led by Advance Venture Partners and included participation from Stripes, First Round Capital, Qiming Venture Partners and Laerdal Million Lives Fund. In total, Boulder Care has raised about $85 million.

By Marissa Plescia

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

Hospitals Artificial Intelligence,

Why Allegheny Health Network Created Its Own Chat-GPT For Employees

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer.

By Katie Adams

Consumer / Employer, Health Tech

Lyra Health Announces Mental Health Offering for Teens

Lyra Care for Teens will be available starting in June. Patients will gain access to therapists who specialize in evidence-based treatments and personalized digital lessons.

By Marissa Plescia

Pharma, BioPharma

Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro

Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro.

By Frank Vinluan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

MedCity Influencers

Next-Generation Nursing

Virtual observation programs can help improve care, help better staff units, and help give nurses the support they need.

By Holly Miller

Pharma, BioPharma

Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush

GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.

By Frank Vinluan

Partnership Post

When Investment Rhymes with Canada

Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.

By Julien Rosan and Tina Kotrych - Global Affairs Canada

Health Tech

Is the Healthcare Industry Embracing Risk in Its Contracts?

As the healthcare industry slowly moves toward value-based care, healthcare companies are thinking about taking on risk. During a panel at MedCity News’ INVEST conference, healthcare leaders shared some key ideas about how the industry is embracing risk in its contracts.

By Katie Adams

Health Tech

Hims & Hers Offers Access to GLP-1s Starting At $199 A Month

Hims & Hers is now providing access to compounded GLP-1s. Patients also receive unlimited medical consultations with a licensed provider.

By Marissa Plescia

MedCity Influencers

Unlocking Better Health: The Role of Personal Health Literacy in Medicare Advantage Enrollment

The impact of personal health literacy on seniors

By Karl Ulfers

Startups

Canadian Women’s Health Medtech Startup Wins Over Audience at MedCity INVEST

Fem Therapeutics won the audience choice award in the Canadian PItch contest at MedCity INVEST in Chicago this week. It competed with Reach Orthopaedics , PragmaClin Research, and OPTT Health.

By Stephanie Baum

Health Tech

What Frustrates 3 Women’s Health Execs

There have been several advancements in the women's health space, but we still have a long way to go, execs said during a recent panel.

By Marissa Plescia

Health Tech, Providers

5 Things to Know About the Sorry State of Healthcare Cybersecurity

During a fireside chat at MedCity News’ INVEST conference, Nitin Natarajan — deputy director at the Cybersecurity and Infrastructure Security Agency (CISA) — shared some key ideas that people need to understand about the current state of cybersecurity in the healthcare industry. For instance, he reminded us that things won’t get better overnight, and that cybersecurity requires an all-hands-on deck approach.

By Katie Adams

BioPharma, Pharma

Biogen Immunology Strategy Comes Into Focus With $1B HI-Bio Acquisition

Biogen’s acquisition of Human Immunology Biosciences brings a drug candidate with potential applications in multiple immune-mediated disorders. The deal comes just prior to the scheduled presentation of clinical data in two of them.

By Frank Vinluan

MedCity Influencers

Allying With Patients to Make Every Cure Possible

To win the battle against rare diseases, drug developers must work hand-in-hand with patients.

By Sharon King